RUNA digital repository

    • Español
    • Galego
    • English
  • English 
    • Español
    • Galego
    • English
  • Login
RUNABibliosaúdeXunta de galicia. Consellería de sanidadeServicio Galego de saúde
  • REPOSITORY
  • ABOUT US
    • About RUNA
    • Normative
    • Sergas Policy
  • HELP
    • Help
    • FAQ
  •   RUNA Home
  • Scientific publication
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Indoleamine, 2-3 dioxygenase activity could be an early marker of graft rejection in heart transplantation

Barge Caballero, Eduardo; Crespo Leiro, Marisa; Domenech García, Nieves; Castro Beiras, Alfonso; Suárez Fuentetaja, Natalia; Paniagua Martín, María Jesús; Grille Cancela, Zulaika; Marzoa Rivas, Raquel; Muñiz García, Javier; Pombo Otero, Jorge
Thumbnail
Statistics
Statistics
View Usage Statistics
Identifiers
Identifiers
URI: http://hdl.handle.net/20.500.11940/7790
PMID: 23146482
DOI: 10.1016/j.transproceed.2012.09.036
ISSN: 0041-1345
Full record
Services
Services
RISMendeleyLinksolver
Files view or download
Files view or download
Transplant Proc . 2012 Nov;44(9):2645-8. (329.6Kb)
Date issued
2012
Journal title
TRANSPLANTATION PROCEEDINGS
Type of content
Artigo
DeCS
Rechazo de Injerto | Trasplante de Corazón | Indolamina-Pirrol 2,3,-Dioxigenasa
MeSH
Graft Rejection | Graft Survival | Supervivencia de Injerto | Heart Transplantation | Indoleamine-Pyrrole 2,3,-Dioxygenase
Abstract
Background: The indoleamine, 2-3 dioxygenase (IDO) is an inducible intracellular enzyme with immunosuppressive effects mainly on lymphocyte populations. It has been postulated that indirect determination of IDO serum activity may be a marker of renal graft rejection, but its potential usefulness in heart transplantation (HT) is unknown. Methods: This longitudinal study included 98 HT patients (83% males) who survived ≥1 year. Mean age was 54.14 ± 11.57 years. Serum IDO activity was analyzed one month after HT by means of high performance liquid chromatography and correlated with the cumulative incidence of acute rejection (AR) during one-year follow-up. AR was defined as biopsy-proven ≥ ISHLT grade 2R rejection or empirically treated non-biopsy-proven rejection. The study sample was divided into two groups: AR group (n = 51), including patients who experienced at least one AR episode during the first year after HT; No-AR group (N = 47), including the remaining patients. Results: Mean serum IDO activity one month after HT was significantly higher (P = .021) in the AR group (3.32 ± 1.56) than in the no-AR group (2.62 ± 1.35). No significant association between serum IDO activity and gender (male: 3.1 ± 1.56, women: 2.43 ± 0.99, P = .092), recipient age (r = -.07, P = .943) or donor age (r = 0.108, P = 0.293) was observed. By means of binary logistic regression, an odds ratio of 1.4 [CI 95%: 1.033-1.876, P = .03] per unit increase of act-IDO was estimated, with no significant modification upon forced adjustment for age and sex. Mean glomerular filtration rate 1 month after HT was 67.01 ± 28.51 mL/min/m(2). No significant correlation between this parameter and serum IDO activity was observed (r = .160, P = .117). Conclusions: Our study suggests that serum IDO activity one month after HT might be associated with a higher risk of AR during one-year follow-up. This association seems to be independent of recipient gender, age or renal function.

Browse

All of RUNACollectionsCentersAuthorsTitlesDeCSMeSHCIETypes of contentThis CollectionCentersAuthorsTitlesDeCSMeSHCIETypes of content

Statistics

View Usage Statistics

OF INTEREST

About Open AccessCopyright
TwitterRSS
Xunta de Galicia
© Xunta de Galicia. Información mantida e publicada na internet pola Consellería de Sanidade o Servizo Galego de Saúde
Legal warning | RSS
Galicia